Please wait while the formulary information is being retrieved.
Drug overview for PLERIXAFOR (plerixafor):
Generic name: PLERIXAFOR (pler-IX-a-for)
Drug class: CXCR4 Chemokine Receptor Antagonists
Therapeutic class: Hematological Agents
Plerixafor, a CXCR4 chemokine-receptor antagonist, is a hematopoietic stem cell mobilizer.
No enhanced Uses information available for this drug.
Generic name: PLERIXAFOR (pler-IX-a-for)
Drug class: CXCR4 Chemokine Receptor Antagonists
Therapeutic class: Hematological Agents
Plerixafor, a CXCR4 chemokine-receptor antagonist, is a hematopoietic stem cell mobilizer.
No enhanced Uses information available for this drug.
DRUG IMAGES
PLERIXAFOR 24 MG/1.2 ML VIAL
The following indications for PLERIXAFOR (plerixafor) have been approved by the FDA:
Indications:
Peripheral mobilization of hematopoietic stem cells
Professional Synonyms:
None.
Indications:
Peripheral mobilization of hematopoietic stem cells
Professional Synonyms:
None.
The following dosing information is available for PLERIXAFOR (plerixafor):
The recommended adult dosage of plerixafor is 0.24 mg/kg (based on actual body weight) daily for up to 4 consecutive days. Plerixafor is given concomitantly with filgrastim as part of the hematopoietic stem cell mobilization regimen.
Treatment with plerixafor should only begin after the patient has received the initial 4 doses of filgrastim. Plerixafor should be administered in the evening, approximately 11 hours prior to a scheduled apheresis session; the filgrastim dose should be administered in the morning prior to apheresis.
Dosage may be increased according to changes in weight, but the maximum dosage should not exceed 40 mg once daily.
Treatment with plerixafor should only begin after the patient has received the initial 4 doses of filgrastim. Plerixafor should be administered in the evening, approximately 11 hours prior to a scheduled apheresis session; the filgrastim dose should be administered in the morning prior to apheresis.
Dosage may be increased according to changes in weight, but the maximum dosage should not exceed 40 mg once daily.
Plerixafor is administered by subcutaneous injection. The drug is available in single-use vials; any unused portion should be discarded.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| PLERIXAFOR 24 MG/1.2 ML VIAL | Maintenance | Adults inject 0.24 mg/kg up to a maximum dose of 40mg by subcutaneous route once daily for 4 days |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| PLERIXAFOR 24 MG/1.2 ML VIAL | Maintenance | Adults inject 0.24 mg/kg up to a maximum dose of 40mg by subcutaneous route once daily for 4 days |
The following drug interaction information is available for PLERIXAFOR (plerixafor):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for PLERIXAFOR (plerixafor):
Drug contraindication overview.
The manufacturer states there are no contraindications to the use of plerixafor.
The manufacturer states there are no contraindications to the use of plerixafor.
There are 2 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Lactation |
| Leukemia |
There are 6 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Chronic kidney disease stage 3A (moderate) GFR 45-59 ml/min |
| Chronic kidney disease stage 3B (moderate) GFR 30-44 ml/min |
| Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min |
| Chronic kidney disease stage 5 (failure) GFr<15 ml/min |
| Nontraumatic splenic rupture |
| Pregnancy |
There are 2 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Kidney disease with likely reduction in glomerular filtration rate (GFr) |
| Thrombocytopenic disorder |
The following adverse reaction information is available for PLERIXAFOR (plerixafor):
Adverse reaction overview.
The most common adverse events (occurring in at least 5% of patients in controlled clinical trials) reported with the combination of plerixafor and filgrastim included diarrhea, nausea, injection site reactions, fatigue, headache, arthralgia, dizziness, vomiting, flatulence, and insomnia.
The most common adverse events (occurring in at least 5% of patients in controlled clinical trials) reported with the combination of plerixafor and filgrastim included diarrhea, nausea, injection site reactions, fatigue, headache, arthralgia, dizziness, vomiting, flatulence, and insomnia.
There are 8 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Anaphylaxis Dyspnea Hypotension Hypoxia Leukocytosis Nontraumatic splenic rupture Splenomegaly Thrombocytopenic disorder |
There are 29 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Arthralgia Diarrhea Dizziness Fatigue Flatulence Headache disorder Injection site sequelae Nausea Vomiting |
Abdominal distension Acute abdominal pain Constipation Dyspepsia Erythema Hyperhidrosis Hypoesthesia Hypokalemia Hypomagnesemia Insomnia Malaise Musculoskeletal pain Myalgia Xerostomia |
| Rare/Very Rare |
|---|
|
Dream disorder Nightmares Orthostatic hypotension Periorbital edema Syncope Urticaria |
The following precautions are available for PLERIXAFOR (plerixafor):
Safety and efficacy not established in pediatric patients younger than 18 years of age.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Category D. (See Users Guide). (See Fetal/Neonatal Morbidity and Mortality, under Cautions: Warnings/Precautions.)
It is not known if plerixafor is distributed into human milk. Because many drugs are distributed into human milk and because of the potential for serious adverse effects of plerixafor in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into the account the importance of the drug to the woman.
No substantial differences in safety or efficacy relative to younger adults, but increased sensitivity cannot be ruled out.
The following prioritized warning is available for PLERIXAFOR (plerixafor):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for PLERIXAFOR (plerixafor)'s list of indications:
| Peripheral mobilization of hematopoietic stem cells | |
| Z52.011 | Autologous donor, stem cells |
Formulary Reference Tool